Tramadol - Avenue Therapeutics
Alternative Names: AVE-901; IV tramadol - Revogenex/Avenue Therapeutics; RVX 109; Tramadol hydrochloride - Revogenex/Avenue Therapeutics; Tramadol intravenous - Revogenex/Avenue TherapeuticsLatest Information Update: 02 May 2024
At a glance
- Originator Revogenex
- Developer Avenue Therapeutics
- Class Anisoles; Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Postoperative pain
Most Recent Events
- 02 May 2024 Avenue Therapeutics submits an NDA application under the 505(b) regulatory pathway for Tramadol
- 04 Jan 2024 Avenue Therapeutics and the US FDA reaches final agreement on the study design and analysis approach of the phase III safety study for Tramadol (IV)
- 25 Jul 2023 Avenue Therapeutics plans a phase III trial for Postoperative pain in 2023 (IV)